EDAP Partners With PanAm HIFU to Offer Ablatherm(R)-HIFU to Prostate Cancer Patients in Cancun, Mexico
16 March 2012 - 12:23AM
EDAP TMS SA (Nasdaq:EDAP), a global leader in therapeutic
ultrasound, announced today that it will partner with PanAm HIFU to
offer minimally invasive HIFU treatment to North American prostate
cancer patients, with the installation of an Ablatherm device in
Cancun, Mexico in the near future. PanAm HIFU is a urology practice
located in Sarasota, FL that provides prostate cancer patients
access to Ablatherm-HIFU treatments in London, England and Cancun,
Mexico.
Marc Oczachowski, Chief Executive Officer of EDAP TMS,
commented, "Since we regained distribution rights for our
Ablatherm-HIFU device in Canada and the Caribbean in January this
year, we have received many requests from urologists in the U.S. to
be trained on and have access to Ablatherm HIFU at offshore
locations. We are very pleased to announce that we signed a
partnership agreement with PanAm HIFU and its medical team that is
experienced in treating prostate cancer with HIFU
technology. This team has experience in using EDAP's Ablatherm
technology in the United Kingdom. Our new partnership agreement
will give PanAm HIFU access to our Ablatherm HIFU technology in
Cancun, Mexico to treat their prostate cancer patients starting in
April 2012."
Dr. Ronald Wheeler, M.D., urologist and medical director of
PanAm HIFU, commented, "We are delighted to offer this beautiful
venue to our patients and to those of other U.S. physicians, who
may want to be trained on this exciting robotic Ablatherm
technology. Several of our patients have reported positive outcomes
after receiving focal prostate cancer treatment with EDAP's
Ablatherm-HIFU device. Cancun offers spectacular 'medical tourism'
as well as five-star hospital facilities. Our website,
www.panamhifu.com, provides information on the Cancun treatment
venue."
About EDAP TMS SA
EDAP TMS SA develops and markets Ablatherm®, the most advanced
and clinically proven choice for high-intensity focused ultrasound
(HIFU) treatment of localized prostate cancer. HIFU treatment is
shown to be a minimally invasive and effective treatment option
with a low occurrence of side effects. Ablatherm-HIFU is generally
recommended for patients with localized prostate cancer (stages
T1-T2) who are not candidates for surgery or who prefer an
alternative option, or for patients who failed radiotherapy
treatment. Approved in Europe as a treatment for prostate cancer,
Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently
undergoing evaluation in a multi-center U.S. Phase II/III clinical
trial under an Investigational Device Exemption (IDE) granted by
the FDA, the ENLIGHT U.S. clinical study. The Company also is
developing this technology for the potential treatment of certain
other types of tumors. EDAP TMS SA also produces and commercializes
medical equipment (the Sonolith® range) for treatment of urinary
tract stones using extra-corporeal shockwave lithotripsy (ESWL).
For more information on the Company, please visit
http://www.edap-tms.com, and http://www.hifu-planet.com.
CONTACT: Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 72
bconfort@edap-tms.com
Investors:
Stephanie Carrington
The Ruth Group
646-536-7017
scarrington@theruthgroup.com
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2023 to Jul 2024